INDP Stock Overview
A clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Indaptus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.91 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.84 |
| Beta | 1.06 |
| 1 Month Change | -9.08% |
| 3 Month Change | -22.29% |
| 1 Year Change | -48.75% |
| 3 Year Change | -83.96% |
| 5 Year Change | n/a |
| Change since IPO | -89.75% |
Recent News & Updates
Recent updates
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?
Mar 27
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?
Aug 15Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45
Aug 08Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications
Sep 29Shareholder Returns
| INDP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.02% | -3.3% | -0.4% |
| 1Y | -48.8% | -2.7% | 24.8% |
Return vs Industry: INDP underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: INDP underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| INDP volatility | |
|---|---|
| INDP Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INDP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INDP's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Jeff Meckler | indaptusrx.com |
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. Fundamentals Summary
| INDP fundamental statistics | |
|---|---|
| Market cap | US$9.27m |
| Earnings (TTM) | -US$14.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs INDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.89m |
| Earnings | -US$14.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INDP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:27 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Indaptus Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |